GlassScriptPhysician profile
Sandra R Flores
NPI 1437206208
$6,297.38
in general payments reported to CMS, 2019-2025
24 companies · $682 in 2025
The $682 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,091 · 2020: $787 · 2021: $390 · 2022: $542 · 2023: $918 · 2024: $887 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,486.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,761.77 | 2019-2025 | Total30, Dailies Total1, Precision 1 |
| Sun Pharmaceutical Industries INC. | $491.75 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $453.48 | 2022-2025 | Miebo, Xiidra |
| Allergan, INC. | $432.49 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $369.60 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $354.84 | 2019-2021 | |
| Shire North American Group INC | $304.42 | 2019 | |
| Oyster Point Pharma, INC. | $293.60 | 2022-2024 | Tyrvaya |
| Coopervision INC. | $264.73 | 2022-2023 | Misight Contact Lens, Biofinity Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $173.91 | 2019-2020 | |
| Abbvie INC. | $171.66 | 2022-2024 | |
| Tarsus Pharmaceuticals, INC. | $164.44 | 2025 | Xdemvy |
| Harrow Eye, LLC | $148.46 | 2025 | Vevye |
| Lkc Technologies, INC. | $137.05 | 2024 | |
| Rxsight INC | $116.54 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $115.61 | 2023 | Oxervate |
| Biotissue Holdings INC. | $115.61 | 2023 | |
| Eyevance Pharmaceuticals LLC | $108.52 | 2019-2020 | |
| Genzyme Corporation | $100.00 | 2019 | |
| Amgen INC. | $86.32 | 2024 | Tepezza |
| Biosense Webster, INC. | $53.81 | 2023 | Carto 3 |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Novartis Pharmaceuticals Corporation | $25.51 | 2020-2021 | |
| Becton, Dickinson and Company | $14.46 | 2024 | Bd Max System, Bd Max Instrument |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.